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Abstract 
 
CREB-binding protein (CBP) and p300 are transcriptional coactivators involved in numerous 
biological processes that affect cell growth, transformation, differentiation, and development. In 
this study, we provide evidence of the involvement of homeodomain-interacting protein kinase 2 
(HIPK2) in the regulation of CBP activity. We show that HIPK2 interacts with and 
phosphorylates several regions of CBP. We demonstrate that serines 2361, 2363, 2371, 2376, 
and 2381 are responsible for the HIPK2-induced mobility shift of CBP C-terminal activation 
domain. Moreover, we show that HIPK2 strongly potentiates the transcriptional activity of CBP. 
However, our data suggest that HIPK2 activates CBP mainly by counteracting the repressive 
action of cell cycle regulatory domain 1 (CRD1), located between amino acids 977 and 1076, 
independently of CBP phosphorylation. Our findings thus highlight a complex regulation of CBP 
activity by HIPK2, which might be relevant for the control of specific sets of target genes 
involved in cellular proliferation, differentiation and apoptosis. 
 
 
Keywords: transcriptional regulation; coactivator; CBP; protein kinase; HIPK2. 
 
Abbreviations: BDNF, brain-derived neurotrophic factor; CBP, CREB-binding protein; C/EBP, 
CCAAT/enhancer binding protein; CRD1, cell cycle regulatory domain 1; CREB, cAMP-
response element binding protein; CtBP, C-terminal-binding protein; DYRK, dual-specificity 
tyrosine-regulated kinases; HIPK2, homeodomain-interacting protein kinase 2; KD, kinase dead; 
JNK, Jun N-terminal kinase; Pin1, peptidyl-prolyl-cis-trans-isomerase; TGF-, Transforming 
growth factor beta. 
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1. Introduction 
 
Homeodomain-interacting protein kinase 2 (HIPK2) is a serine/threonine kinase belonging to 
the subfamily of dual-specificity tyrosine-regulated kinases (DYRK) [1, 2]. It was initially 
identified as a corepressor that potentiates the repressor activities of NK homeoproteins and was 
cloned by its ability to interact with Nkx-1.2 [3]. Since then, HIPK2 has been shown to be a 
pleiotropic regulator of cell death, having proapoptotic and antiproliferative effects in several 
cell types. Apoptosis evoked by ultraviolet irradiation requires activation of HIPK2 that, in turn, 
phosphorylates p53 at Ser46 [4, 5]. Activation of p53 is known to rely on a phosphorylation-
acetylation cascade that increases its site-specific DNA-binding [6]. The transcriptional 
coactivators CREB-binding protein (CBP) or p300 act as acetylating enzymes in this cascade. 
HIPK2 is necessary in vivo for efficient p300/p53 co-recruitment onto apoptotic promoters, and 
p53 modifications both at Ser46 and Lys382 are necessary for p53 apoptotic transcription [7]. 
Consistent with the foregoing, phosphorylation at Ser46 by HIPK2 has been shown to augment 
CBP-dependent acetylation and the transcriptional activity of p53; moreover, the Ser46Ala 
mutant of p53 is not acetylated by CBP at Lys382 [4]. However, despite the absence of 
phosphorylable Ser46 residue, the transactivating potential of this point mutant is still strongly 
enhanced by cotransfection of HIPK2 in reporter assays [4], thus suggesting a putative direct 
effect of HIPK2 on CBP. 
HIPK2 promotes apoptosis through p53-independent pathways as well. For example C-
terminal-binding protein (CtBP) is phosphorylated by HIPK2 at Ser422, and this phosphorylation 
targets CtBP to degradation and contributes to the UV-induced apoptotic response [8, 9]. TGF-
induced Jun N-terminal kinase (JNK) activation and apoptosis is also positively regulated by 
HIPK2 [10]. Furthermore, HIPK2 participates in a cascade leading to the phosphorylation 
induced degradation of the proto-oncogene product c-Myb [11]. 
Interestingly, HIPK2’s role can also be anti-apoptotic. For instance, HIPK2 is required for 
TGF--mediated survival of midbrain dopamine neurons [12]. Moreover, HIPK2-induced 
phosphorylation of the transcription factor CREB at Ser271 favors CBP recruitment and 
expression of brain-derived neurotrophic factor (BDNF), thus decreasing SH-SY5Y 
neuroblastoma cells apoptosis induced by the DNA damaging agent etoposide [13]. 
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Recently a modeling approach has revealed a role of HIPK2 in adipocyte differentiation, and 
experiments aimed at confirming this prediction have indeed shown that the expression level of 
HIPK2 increases 10 fold during adipocytic differentiation [14]. Furthermore, the white adipose 
tissue deposits of HIPK2 knock-out mice are smaller and the size of the adipocytes is reduced in 
these animals. The necessity of HIPK2 in this context is equally well demonstrated in 3T3 
fibroblast culture, being an established in vivo model of adipocytic differentiation [15]. 
Furthermore, HIPK2 collaborates with the transcription factor AML-1 and the coactivator p300 
to increase transcription at AML-1-dependent promoters. AML-1 is phosphorylated by HIPK2 
and subsequently targets p300 to phosphorylation by the same kinase [16]. In accordance with 
these results, double transgenic mice lacking HIPK2 and HIPK1 show deficits in hematopoiesis, 
angiogenesis and vasculogenesis [16]. 
The coactivators CBP and p300 are believed to interact with hundreds of different 
transcription factors (for review, see Refs [17, 18]). Both coactivators have an intrinsic 
acetyltransferase activity, which allow them to acetylate histones, and thereby modify chromatin 
structure, as well as transcription factors like p53, as already mentioned. CBP and p300 also 
function as adaptors between tissue- and sequence-specific transcription factors and the general 
transcriptional machinery, and are thus believed to activate gene transcription by recruiting basal 
transcription factors. Although CBP and p300 are known to be phosphorylated in various 
conditions, relatively little is known about the protein kinases that target these coactivators, their 
phosphorylation sites and the effect of these post-translational modifications on CBP and p300 
functions. 
In this study, we report that HIPK2 interacts with and phosphorylates CBP at multiple sites. 
We show that HIPK2 phosphorylates a cluster of five serines and thus induces a mobility shift of 
a CBP C-terminal fragment. We demonstrate that HIPK2, but not its kinase-dead mutant, 
increases the transactivating potential of CBP. However, this activation of CBP by HIPK2 does 
not seem to be due to its phosphorylation, but rather through the action of this kinase on factors 
repressing CBP functions. 
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2. Materials and methods 
 
2.1. Plasmids 
 
pcDNA3-CBP-2FLAG, pcDNA3-CBP1680-2441-2FLAG, pcDNA3-CBP1680-1892-2FLAG, 
pcDNA3-CBP1893-2441-2FLAG, and the Gal4-LUC (luciferase) reporter were described in 
Kovács et al. [19]. To construct the expression plasmids for the CBP fragments, PCR-generated 
DNA sequences encoding CBP amino acids 2-250, 251-450, 451-682, 683-900, 901-1100, 1101-
1231, 1232-1711, 1893-2160, 2161-2441, and 1680-2160 were inserted into a modified pcDNA3 
vector containing sequences encoding a nuclear localization sequence at the N-terminus and 2 
FLAG epitopes at the C-terminus. Individual or combined serine to alanine mutations at position 
2361, 2363, 2371, 2376, and 2381 were introduced in pcDNA3-CBP1680-2441-2FLAG with the 
QuikChange site-directed mutagenesis kit (Stratagene). To construct the expression plasmids for 
the various Gal4-CBP fusion proteins, full-length CBP cDNA or PCR-generated DNA sequences 
encoding CBP amino acids 1-450, 1-682, 1-900, 1-1100, 1-1231, 1232-1711, and 1232-2441 
were inserted into a modified pcDNA3 vector containing sequences encoding the Gal4 DNA 
binding domain (amino acids 1 to 147) at the N-terminus and 2 FLAG epitopes at the C-
terminus. pcDNA3-Gal4-CBP1-682+977-1076-2xFLAG was constructed by subcloning a PCR-
amplified DNA sequence encoding CBP amino acids 977-1076 into pcDNA3-Gal4-CBP1-682-
2xFLAG. Mutant pcDNA3-Gal4-CBP-2xFLAG with the 5 serine to alanine mutations was 
generated by swapping a C-terminal restriction fragment with the counterpart bearing the 
mutations that was taken from mutant pcDNA3-CBP1680-2441-2FLAG. pCMV-SPORT6-HIPK2 
(cDNA clone MGC:36065, IMAGE:5368577) driving the expression of mouse HIPK2 was 
obtained from MRC geneservice (Cambridge, UK). The kinase-dead mutant pCMV-SPORT6-
HIPK2 (K221R) was generated from pCMV-SPORT6-HIPK2 with the QuikChange site-directed 
mutagenesis kit (Stratagene). pCMV-HIPK2-FLAG is a kind gift of S. Soddu (Regina Elena 
Cancer Institute, Rome, Italy), and was described in D’Orazi et al. [5]. To produce the 10 
purified GST-CBP fusion proteins used in the in vitro kinase assays, DNA sequences encoding 
CBP amino acids 2-250, 251-450, 451-682, 683-900, 901-1100, 1101-1231, 1232-1711, 1680-
1892, 1893-2160, and 2161-2441 were transferred from the corresponding pcDNA3-CBP-
2FLAG constructs into pGEX-KG or pGEX-4T3 (Pharmacia). Mutant pGEX-CBP2161-2441-
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2FLAG with the 5 serine to alanine mutations between amino acids 2361 and 2381 was 
constructed by cloning into pGEX-4T3 a fragment encoding CBP amino acids 2161-2441 and 2 
FLAG epitopes, which was amplified by PCR using as a template pcDNA3-CBP1680-2441-
2FLAG with the 5 serine to alanine mutations. All the constructs were verified by sequencing. 
Restriction maps and sequences of all the constructs described
 
above are available upon request.  
 
2.2. Cell culture and transfection assays 
 
HEK 293T cells (American Type Culture Collection, CRL-11268) were cultured on gelatin-
coated plates in high glucose GLUTAMAX Dulbecco’s modified Eagle’s medium (Invitrogen) 
containing 10% heat-inactivated newborn calf serum (Invitrogen), 100 U/ml penicillin G, and 
100 µg/ml streptomycin sulfate (Invitrogen). Calcium phosphate transfection assays were 
performed according to an improved protocol described by Jordan et al. [20]. Briefly, HEK 293T 
cells were seeded at 8 x 10
5
 cells per 60-mm plate, and 24 hr later, were transiently transfected 
with 8 or 9 µg of total DNA. The cell culture medium was changed 8hr later, and, 24 hr after 
transfection, cellular lysates were prepared for luciferase assays or immunoblot analysis. 
 
2.3. Preparation of cellular extracts 
 
To perform experiments with recombinant proteins expressed in HEK 293T cells, whole cell 
extracts were prepared by lysing the cells in 50 mM Hepes pH 7.6, 250 mM NaCl, 0.2 mM 
EDTA, 0.5% NP-40, 1mM DTT, 10 M NaF and 10 M Na3VO4 for 30 min at 4°C. Then, the 
extracts were cleared by centrifugation at 16’000xg for 10 min. To prevent proteolysis, a 
protease inhibitor cocktail for mammalian tissue (Sigma) and calpain inhibitor were included in 
the lysis buffer. 
 
2.4. Immunoblot analysis 
 
After separation on SDS-polyacrylamide gels (SDS-PAGE), the proteins were transferred to 
PVDF membranes with a semi-dry blotting system (BioRad) for 45 min at 20 V as previously 
described [19]. Blots were blocked overnight at 4°C in TBST containing 10 mM Tris-HCl, 150 
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mM NaCl pH 7.4, and 0.05% Tween-20, supplemented with, 10% skim milk powder, and 1% 
BSA. Blots were subsequently incubated with a primary antibody in TBST plus 1% skim milk 
powder for 2 hr at room temperature. FLAG-tagged CBP fragments were detected with anti-
FLAG M2 monoclonal antibody (Sigma), and HIPK2 as well as its kinase-dead mutant were 
monitored with a goat anti-HIPK2 polyclonal antibody (Santa Cruz). Vinculin was used as a high 
molecular weight protein loading control and was detected with a rabbit anti-vinculin 
monoclonal antibody (Abcam ab129002). Finally, PVDF membranes were incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies, and developed using 
chemiluminescence detection kits (enhanced chemiluminescence, Amersham, or SuperSignal® 
West Femto, Pierce). 
 
2.5. GST proteins 
 
GST fusion proteins were expressed in Escherichia coli (BL21-Codon Plus, Stratagene) and 
purified over glutathione-Sepharose beads (Sigma). 
 
2.6. In vitro kinase assays 
 
Kinase assays were either performed with FLAG-tagged full-length HIPK2 purified by 
immunoprecipitation from transfected HEK 293T cells , or with a purified recombinant N-
terminal fragment of human HIPK2 (amino acids 165-564, Upstate cell signaling solutions) 
according to the manufacturer’s protocol. Recombinant HIPK2 (25 ng) was incubated with GST-
CBP fragments (3 µM in Fig. 3B and 7 µM in Fig. 5B) in 25 l kinase buffer (10 mM MOPS pH 
7.0, 3 mM Tris-HCl pH 7.5, 8 mM NaCl, 22.5 mM Mg acetate, 0.4 mM EDTA, 3 mM sucrose, 
1% glycerol, 0.01% -mercaptoethanol, 0.1 mM DTT, 0.1 mg/ml BSA) in the presence of 10 
Ci [-32P]ATP and 90 M unlabeled ATP for 20 min at 30°C. The reaction was stopped by the 
addition of 3  SDS loading buffer, the products were resolved on a 12% SDS-PAGE, the gel 
was fixed, stained with Coomassie, dried, and 
32
P-labeled proteins were detected by 
autoradiography. 
 
2.7. Co-immunoprecipitation 
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HEK 293T cells were co-transfected with 7.5 g of pSPORT6-HIPK2 and 7.5 g of the 
appropriate CBP fragment or pcDNA3 as indicated in Fig. 4 using the abovementioned calcium 
phosphate method. Twenty-four hours later, cells were lysed in 50 mM Hepes pH 7.6, 150 mM 
NaCl, 0.2 mM EDTA, 0.5% NP-40, 10 M NaF and 10 M Na3VO4 for 30 min at 4°C. Then, 
the extracts were cleared by centrifugation at 16’000xg for 10 min. To prevent proteolysis, a 
protease inhibitor cocktail for mammalian tissue (Sigma) and calpain inhibitor were included in 
the lysis buffer. Whole cell extracts (1 mg) were incubated with 20 l anti-FLAG agarose beads 
(Sigma) for 2 hours at 4 ºC with continuous agitation. Beads were then washed three times in 
lysis buffer, transferred to a new tube, and immunoprecipitated proteins were eluted by boiling in 
30 l SDS-loading buffer. To detect co-immunoprecipitated HIPK2, 10 l of the supernatants 
were separated on a 6% SDS-polyacrylamide gel, whereas 10 l were resolved on a precast 4-
15% gradient SDS-polyacrylamide gel (BioRad) to detect the immunoprecipitated FLAG-tagged 
CBP fragments. HIPK2 and FLAG immunoblot analyses were performed as described above. 
 
2.8. Luciferase Assays 
 
Transfected cells were washed with PBS, lysed in 250 µl 1x Cell Culture Lysis Buffer 
(Promega), and centrifuged in a microcentrifuge for 2 min at 4˚C. To test the samples for 
luciferase activity, 20 µl of the 100-diluted or undiluted supernatant was assayed in a Turner-
Designs TD-20/20 luminometer using 100 µl of Luciferase Assay Reagent (Promega). 
Luciferase activity was normalized to total cellular protein (Bio-Rad Protein Assay). All 
experiments were performed in triplicate. 
 
2.9. Statistical analysis 
We determined statistical differences for the luciferase assays by two-way analysis of variance 
(ANOVA) with a Fisher Least Significant Difference (LSD) post hoc test. 
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3. Results 
 
3.1. HIPK2 interacts with and phosphorylates CBP at multiple sites 
 
We previously reported that the C-terminal region of CBP is phosphorylated by an 
unidentified kinase when it interacts with C/EBP family members [19]. Looking for kinases that 
could be involved in this process, we observed that cotransfection of HIPK2 retarded the band 
corresponding to full-length CBP in SDS-polyacrylamide gels (Figures 1A and 1B). These 
Western blot experiments show a CBP mobility shift only in the presence of HIPK2 and not with 
the kinase-dead (KD) mutant form of HIPK2 (K221R), thus suggesting that HIPK2 
phosphorylates CBP. The HIPK2-induced mobility shift of full-length CBP is more obvious with 
the shortly exposed bands of Figure 1B. The C-terminal FLAG tag allowed for the visualization 
of naturally occurring C-terminal degradation products of full-length CBP that also showed a 
HIPK2-induced mobility shift (Figure 1A, upper panel, lane 2), which indicated that HIPK2 may 
phosphorylate the C-terminal portion of CBP. Indeed, HIPK2, but not the KD mutant, retarded 
the electrophoretic mobility of CBP1680-2441 (Figure 1A) in a similar way to what was observed 
with the C/EBPs [19]. 
To uncover which part of CBP is modified by HIPK2, we generated several FLAG-tagged 
CBP fragments and verified whether their mobility was changed by pCMV-SPORT6-HIPK2 
cotransfection (Figure 2). The following fragments showed a change in electrophoretic mobility: 
CBP5, CBP10, CBP9-10 (see the description of the fragments in Figure 2A). For an unknown 
reason, CBP9 was not expressed at detectable levels in eukaryotic cells, and thus could not be 
tested. These results suggested that in addition to the C-terminal part of CBP, the N-terminus can 
also be a substrate of HIPK2. 
To show that the altered electrophoretic mobility of CBP fragments is indeed due to 
phosphorylation, we performed in vitro phosphorylation experiments with bacterially produced 
GST-CBP fragments and radiolabeled phosphate using either FLAG-tagged HIPK2 
immunoprecipitated from lysates of transfected HEK 293T cells (Figure 3A), or human 
recombinant active HIPK2 (Figure 3B). In both experiments, the CBP fragments 4, 5, 9, and 10 
were phosphorylated (Figures 3A and 3B). This further confirmed that the mobility shifts of 
CBP5 and CBP10 were probably due to phosphorylation that triggered profound conformational 
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changes in these CBP fragments. Furthermore, these in vitro phosphorylation experiments 
clearly showed that CBP4 and CBP9 are phosphorylated by HIPK2 as well. In contrast, no 
phosphorylation could be observed for the following fragments: CBP1-3, CBP6, CBP7 and 
CBP8 (Figures 3A and 3B). Together, these data indicate that CBP could be phosphorylated by 
HIPK2 mainly between amino acids 683-1100 and at the C-terminus between amino acids 1893-
2441. 
The interaction between HIPK2 and CBP has already been documented; however, the 
interacting domains of CBP have not been mapped in detail [4]. Given that our results had shown 
that CBP was phosphorylated at remotely situated sites, we asked whether HIPK2 contacted CBP 
at multiple regions. To address this question we co-transfected HEK 293T cells with equal 
amounts of pCMV-SPORT6-HIPK2 and various pcDNA3-CBP-2xFLAG constructs, 
immunoprecipitated FLAG-tagged CBP fragments and analyzed immunoprecipitates by western 
blot for the presence of HIPK2. We detected strong interaction between HIPK2 and full-length 
CBP, whereas HIPK2 was not present in immunoprecipitates of the negative control lacking 
FLAG-tagged CBP (Figure 4). CBP8-9 pulled down similar levels of HIPK2 as full-length CBP, 
whereas CBP8-9-10 and CBP9-10 showed somewhat weaker interaction. From these data, we 
inferred that the most important region for the interaction lie between amino acids 1893 and 
2160, whereas the C-terminal fragment 2161-2441 rather inhibits the recruitment of HIPK2. 
Unfortunately, we could not test this hypothesis, because CBP9 could not be expressed in HEK 
293T cells. CBP7, harboring the histone-acetyltransferase (HAT) domain, and CBP3, lying next 
to the N-terminal phosphorylation sites, both recruit HIPK2, however, to a weaker extent than 
the C-terminal fragments (Figure 4). These results thus suggest that HIPK2 interacts directly or 
indirectly with several regions of CBP. Moreover, HIPK2 is phosphorylating CBP at multiple 
sites, some of which could be within the interacting region (CBP9) and the others appear to be 
located within adjacent regions (CBP4, CBP5, CBP10). 
 
3.2. Phosphorylation of five serines at the C-terminus of CBP is responsible for the mobility shift 
of CBP1680-2441 induced by HIPK2 
 
To identify residues targeted by HIPK2 at the C-terminus of CBP, we took advantage of the 
fact that phosphorylated CBP1680-2441 is strongly retarded in SDS-polyacrylamide gels. Within 
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this C-terminal fragment, we mutated to an alanine several serines and threonines that were 
followed by a proline, and monitored by Western blot the corresponding changes in the 
migration of CBP1680-2441 in the presence of HIPK2. Among the various putative phosphorylation 
sites that were tested, we found a cluster of five serines, located at positions 2361, 2363, 2371, 
2376 and 2381, whose mutation to alanine almost completely abolished the HIPK2-induced 
mobility shift of CBP1680-2441 (Figure 5A). Individual point mutations had either no effect (1,2,4) 
or a marginal one (3,5), whereas the combination of the point mutations in two groups (1,2 and 
3,4,5) decreased the mobility shift of the fragment by approximately a half. Combining the two 
groups of point mutations nearly eliminated CBP mobility shift showing that phosphorylation at 
these five phosphoacceptor sites is responsible for the robust conformational change of CBP1680-
2441 (Figure 5A, lower panel). In vitro phosphorylation of wild-type (wt) or mutant (5SA) 
GST-CBP2161-2441 by human recombinant active HIPK2 confirmed that the mutation of the five 
clustered serines decreased CBP phosphorylation (Figure 5B). However, the remaining 
phosphorylation of the mutant also indicated that HIPK2 might phosphorylate other serine or 
threonine residues in CBP2161-2441, although it is possible that in vitro phosphorylation with 
purified proteins might not reflect the physiological conditions that would occur in a cellular 
context. 
 
3.3. HIPK2 enhances the transcriptional activity of CBP mainly by counteracting the repressive 
action of the CRD1 domain 
 
Having found which HIPK2 phosphorylation sites were responsible for the mobility shift of 
CBP1680-2441, we next tested whether the transcriptional activity of CBP was increased in the 
presence of HIPK2 and whether the five serines at the C-terminus that induce a conformational 
change were actually playing a role in this activation. To this end, we examined the 
transactivating potential of Gal4-CBP in the presence or in the absence of cotransfected HIPK2, 
using a Gal4-LUC reporter plasmid (Figure 6). HIPK2 clearly stimulated the transcriptional 
activity of CBP through a process that required its kinase activity, because the kinase-dead (KD) 
mutant form of HIPK2 was ineffective. Nonetheless, the activity of the Gal4-CBP construct, in 
which the 5 serine to alanine mutations had been introduced at the C-terminus, was not different 
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from the wild-type Gal4-CBP construct, suggesting that these phosphorylation sites do not play a 
major functional role, at least in these experimental conditions. 
To further determine through which region of CBP HIPK2 is stimulating its transcriptional 
activity, we first split the molecule into N-terminal and C-terminal halves. The transactivating 
potential of Gal4-CBP1-1231 was increased nearly 50 fold by HIPK2 and was comparable to the 
stimulated activity of Gal4-CBPFL, whereas that of Gal4-CBP1232-2441 showed only a 5 fold 
increase (Figure 7). Gal4-CBP1232-1711, a fragment encompassing the histone acetyltransferase 
domain was activated by HIPK2 only approximately 2 fold. To analyze the strong effect that 
HIPK2 exerted on the transcriptional activity of Gal4-CBP1-1231, we then generated several N-
terminal fragments of CBP fused to the Gal4 DNA-binding domain. Gal4-CBP1-450 and Gal4-
CBP1-682 showed weak and strong transactivating potential, respectively. Neither of these 
fragments was activated by cotransfection of HIPK2 (Figure 7). The basal transcriptional activity 
of Gal4-CBP1-682 was comparable to the activity of Gal4-CBP1-1231 in the presence of HIPK2, 
suggesting the existence of a repressor domain between 683 and 1232 that could be neutralized 
by HIPK2. We further defined the position of this repressor domain by observing that Gal4-
CBP1-900 and Gal4-CBP1-1100 showed high and low basal activity, respectively, and that only 
Gal4-CBP1-1100 was activated by HIPK2 (Figure 7). These observations strongly suggested that 
the repressor domain contained within CBP900-1100 was presumably identical to the CRD1 domain 
first described in p300 [21]. We have shown that CBP900-1100 is indeed phosphorylated by HIPK2 
(Fig. 2 and 3), but a close examination of the murine CBP sequence corresponding to the p300 
CRD1 domain revealed no putative HIPK2 phosphorylation site between amino acids 977 and 
1076, where the CRD1 domain is located, whereas 10 putative phosphorylation sites are present 
in CBP900-1100, mostly between amino acids 900 and 977. Instead of trying to identify which 
serine and threonine residues of CBP900-1100 are phosphorylated by HIPK2, we first determine 
whether the phosphorylation of this CBP fragment by HIPK2 was indeed required to lift CRD1-
mediated inhibition. To this end, we fused Gal4-CBP1-682 to the CBP amino acids 977-1076 
containing the CRD1 domain but devoid of any putative HIPK2 phosphorylation sites, and as 
expected, we observed a strong repressive effect of the CRD1 adjunction (Figure 8). Much to our 
surprise, however, HIPK2 completely abolished the repression exerted by the CRD1 domain. 
The much weaker activation by the kinase-dead (KD) HIPK2 mutant showed that the kinase 
activity of HIPK2 is required to counteract the effect of CRD1, even though this domain of CBP 
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does not contain any putative phosphorylation site for this kinase. Taken together, these results 
provide evidence that HIPK2 mainly enhances the transcriptional activity of CBP by 
counteracting the repressive action of the CRD1 domain through a mechanism that appears to be 
independent of CBP phosphorylation. 
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4. Discussion 
 
The present study provides evidence that HIPK2 interacts with several domains of the 
coactivator CBP and phosphorylates it at multiple sites located between amino acids 683-1100 
and between 1893-2441 at the C-terminus. We identified five HIPK2 phosphorylation sites at 
position 2361, 2363, 2371, 2376, and 2381 that are responsible for the mobility shift of CBP1680-
2441. However, we could not relate the phosphorylation of these five serines to the stimulation of 
the transcriptional activity of Gal4-CBP by HIPK2. Instead, we showed that HIPK2 activates 
Gal4-CBP mainly by lifting the repressive effect of the CRD1 domain located between amino 
acids 977 and 1076. Our data suggest that this derepression is not dependent on CBP 
phosphorylation, but rather on the phosphorylation of other factors acting in the repression 
pathway mediated by the CRD1 domain. Taken together, these findings identify CBP as a new 
substrate of HIPK2 and suggest a complex regulation of CBP activity by this kinase. 
The HIPK2-mediated phosphorylation of CBP identified in the present study is accompanied 
by profound conformational changes as evidenced by the altered electrophoretic mobility of 
CBP901-1100, CBP1680-2441, and full-length CBP. We identified five serine residues as 
phosphoacceptors, all of them being followed by a proline in agreement with the fact that HIPK2 
is a proline-directed serine/threonine kinase. Conformational changes at phosphorylated SP or 
TP sites often occur as a result of prolyl-cis-trans isomerisation and require the enzymatic 
activity of Pin1 (peptidyl-prolyl-cis-trans-isomerase) [22]. Therefore, the conformational change 
at the C-terminus of CBP might rely on Pin1. In this case, the phosphorylation of CBP by HIPK2 
would be a prerequisite for the Pin1-mediated conformational change. Further studies are needed 
to determine whether Pin1 is implicated in this process. 
We previously observed similar mobility shifts of full-length CBP and CBP1680-2441 upon 
C/EBP, -, - co-expression, and phosphatase treatment of CBP1680-2441 showed that its shift 
was indeed due to phosphorylation [19]. Interestingly, the C/EBP-induced mobility shift of 
CBP1680-2441 was not anymore observed when serines 2361, 2363, 2371, 2376, and 2381 were 
replaced by alanines (data not shown). These findings suggest that HIPK2 could be the kinase 
recruited and activated by C/EBPs that phosphorylates the C-terminus of CBP. This is further 
supported by a report that identified HIPK2 as the kinase that phosphorylates p300, the 
functional homolog of CBP, when it interacts with C/EBP [23]. Recently, on the basis of 
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previous work from our laboratory identifying homology boxes in C/EBP proteins [19] the 
structure of a putative complex between C/EBPε and p300 has been described using the crystal 
structure of a chimeric protein containing a segment from each interacting partner [24]. It has 
been proposed that HIPK2 could be a third partner in a complex containing C/EBP and p300, 
and that v-Myc inhibits the activity of C/EBP supposedly by interfering with p300 
phosphorylation, by binding to C/EBP and displacing HIPK2 from the ternary complex [23]. 
This report also demonstrated that HIPK2 phosphorylates serine 2280 of p300, which was 
previously involved with other putative phosphorylation sites in the mobility shift of the C-
terminal part of p300 induced by C/EBP [25]. This serine does not correspond to any of the five 
serines of CBP that were identified in the present study. While we were trying to identify the 
phosphorylation sites responsible for the C/EBP-induced mobility shift of CBP1680-2441, we 
replaced by alanines all the serines and threonines corresponding to mutA and mutB (Ser2280) 
of p300 [25], but this did not decrease the mobility shift of this CBP fragment (data not shown). 
Therefore, it appears that the conformational change of the C-terminal part of CBP and p300 is 
not induced by the homologous HIPK2 phosphorylation sites in these two coactivators, although 
the amino acids sequences responsible for the mobility shift of p300 [25] and CBP (the 5 serines 
identified in the present study) are well conserved in both coactivators. 
In addition to the identification of phosphorylation sites within the C-terminal part of CBP, 
we showed that HIPK2 phosphorylates CBP683-900 and CBP901-1100. These two adjacent regions 
contain 17 SP and TP sites, thus rendering the identification of the HIPK2 phosphorylation sites 
difficult. In a study showing that HIPK2 forms a complex with, and phosphorylates AML1 and 
p300, Aikawa and collaborators described 11 putative HIPK2 phosphorylation sites in the 
corresponding region of p300 [16]. However, these authors did not formally identify which of 
these sites are actually phosphorylated by HIPK2. The mutation of these 11 sites to alanines 
significantly reduced the activation of Gal4-p300 by HIPK2, although the mobility shift of the 
mutant protein did not seem to be different from wild-type Gal4-p300. Eventually, the activation 
of Gal4-p300 by HIPK2 was totally abolished when 23 serines and threonines were replaced by 
alanines at 3 different clusters in p300 [16]. We did not follow the same systematic mutational 
approach to identify the functional HIPK2 phosphorylation sites in CBP, because we were afraid 
that the introduction of so many point mutations might change the properties of CBP in an 
artifactual way. Moreover, our data of Fig. 8, which show that HIPK2 is counteracting the 
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repressive effect of the CRD1 domain that is devoid of phosphorylation site, suggest that HIPK2 
is activating CBP independently of its phosphorylation. 
The CRD1-mediated inhibition of CBP and p300 is mechanistically similar, both coactivators 
can be relieved of the repression by cotransfection of p21 [21], and inhibition seems to involve 
the conjugation of SUMO to both p300 and CBP [25, 26]. However, slight differences exist in 
the manner that CRD1 exerts its effects on the coactivators. The SUMO-modified p300 recruits 
directly HDAC6 that decreases transcriptional activity [26], whereas SUMOylated CBP first 
recruits Daxx, which then brings HDAC2 to the complex [27]. 
To test whether HIPK2 neutralizes CRD1-mediated repression through phosphorylation, we 
generated the Gal4-CBP1-682 + 977-1076 mutant. This mutant contained the first 682 amino acids of 
CBP, which were shown to have a strong activity that was not influenced by HIPK2, fused to a 
region comprising the CRD1 domain, but devoid of HIPK2 phosphorylation sites. As expected, 
the activity of Gal4-CBP1-682 was repressed by the adjunction of the CRD1 domain. Surprisingly 
however, HIPK2 relieved this repression although no putative phosphorylation site was present 
between amino acids 977 and 1076. The likely interpretation of these data is that HIPK2 is 
phosphorylating an upstream factor that acts on the CRD1 domain to derepress CBP. 
 
5. Conclusions 
 
In the present study, we show a complex interplay between HIPK2 and the coactivator CBP: 
(1) HIPK2 interacts with several domains of CBP; (2) HIPK2 phosphorylates CBP at multiple 
sites located between its KIX domain and bromodomain, and within the C-terminal activation 
domain; (3) phosphorylation by HIPK2 of a cluster of five serines at position 2361, 2363, 2371, 
2376, and 2381 induces a conformational change and a mobility shift of CBP1680-2441; (4) HIPK2 
very potently increases the activity of CBP, however, this activation does not seem to depend on 
CBP phosphorylation, but rather on the inactivation of the CRD1 repression domain located 
between amino acids 977 and 1076. Given the multitude of transcription factors interacting with 
CBP and the versatile role of HIPK2, the present study raises the interesting possibility that 
HIPK2-mediated CBP regulation may influence the transcription of a large panel of genes 
involved in apoptosis or alternatively in differentiation and development. 
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Figure legends 
 
Fig. 1. HIPK2 alters the electrophoretic mobility of CBP. (A) Western blot analysis of full-
length CBP (CBPFL) or a C-terminal fragment (CBP1680-2441) co-expressed with HIPK2 in HEK 
293T cells. Equal amounts of pcDNA3-CBP-2xFLAG, or pcDNA3-CBP1680-2441-2xFLAG and 
either pcDNA3 (-), pCMV-SPORT6-HIPK2 (+), or a kinase-dead mutant pCMV-SPORT6-
HIPK2-K221R (KD) were co-transfected, and 24 hr later, cellular extracts were prepared and 
analyzed on a 6% SDS-PAGE, followed by Western immunoblotting using anti-FLAG (top) or 
anti-HIPK2 (bottom) antibodies. The position of full-length CBP or CBP1680-2441 in the absence 
of HIPK2 is indicated by a black arrow, whereas the slow migrating forms of CBP are marked by 
empty arrows. The different migration of the KD mutant compared to HIPK2 is due to its 
inability to autophosphorylate. (B) To better visualize the alteration in electrophoretic mobility 
of full-length CBP, another independent experiment was performed as in (A). Cellular proteins 
were separated on a 6% SDS-PAGE and analyzed by Western immunoblotting using anti-FLAG, 
anti-HIPK2, and anti-vinculin antibodies. The 125 kDa cytoskeletal protein vinculin was used as 
a loading control. A short exposure of chemiluminescence immunodetection is shown in the top 
panel to better appreciate the electrophoretic mobility shift of full-length CBP in the presence of 
active HIPK2 (compare lane 2 to lanes 1 and 3). 
 
 
Fig. 2. HIPK2 induces a mobility shift of two distinct domains of CBP. (A) Schematic 
representation of CBP and its most important domains, with the various CBP fragments used in 
this study (numbers between 2 and 2441 refer to CBP amino acids). CH1-3: Zinc finger domains; 
KIX: kinase inducible domain interacting domain; CRD1: cell cycle regulatory domain 1; BD: 
Bromodomain; HAT: Histone acetyltransferase domain; SID: SRC1 interaction domain; pQ: 
glutamine rich region; AD: activation domain. (B) HEK 293T cells were transfected with various 
FLAG-tagged CBP fragments along with pCMV-SPORT6-HIPK2 (+) or the kinase-dead mutant 
pCMV-SPORT6-HIPK2-K221R (KD) as indicated, and protein extracts were analyzed by SDS-
PAGE and Western immunoblotting with anti-FLAG or anti-HIPK2 antibodies. Empty arrows 
indicate slow migrating forms of CBP fragments that are not visible in the presence of the 
kinase-dead HIPK2 mutant.  
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Fig. 3. In vitro phosphorylation of GST-CBP fragments. (A) Full-length FLAG-tagged HIPK2 
was expressed in HEK 293T cells, immunoprecipitated with anti-FLAG agarose beads, and 
incubated with 2 g of the various purified GST-CBP proteins in the presence of -32P-ATP. 
Numbers 1 to 10 correspond to the fragments described in Figure 2. An extract of non-
transfected HEK 293T cells was used in the control conditions (-). The top panels show the 
autoradiography of the Coomassie-stained gels displayed in the bottom panels. The position of 
the phosphorylated GST-CBP fragments is indicated by an empty arrow. The band above 150 
kDa (
32
P-HIPK2) corresponds to autophosphorylated full-length FLAG-tagged HIPK2. 
Coomassie-stained GST-CBP proteins are localized by arrowheads. (B) Human recombinant 
active HIPK2 (amino acids 165-564) was incubated with the GST-CBP proteins in the presence 
of -32P-ATP. The position of the phosphorylated GST-CBP fragments is indicated by an empty 
arrow (top panel). The band above 50 kDa (
32
P-rHIPK2) corresponds to autophosphorylated 
recombinant HIPK2. Coomassie-stained GST-CBP proteins are localized by arrowheads (lower 
panel). 
 
 
Fig. 4. HIPK2 interacts with C-terminal fragments of CBP. HEK 293T cells were co-transfected 
with equal amounts of pCMV-SPORT6-HIPK2 and pcDNA3-CBP-2xFLAG (CBPFL), or various 
FLAG-tagged CBP fragments. As a negative control, cells were transfected only with pCMV-
SPORT6-HIPK2 (Ctrl). Cell lysates (5%, top panel) and immunoprecipitates with anti-FLAG 
agarose beads were analyzed by immunoblotting with anti-HIPK2 or anti-FLAG antibodies. 
Numbers 1 to 10 correspond to the fragments described in Fig. 2. Arrowheads indicate the 
position of full-length CBP or its various fragments. 
 
 
Fig. 5. Serine to alanine mutation of five clustered residues abolishes the HIPK2-induced 
mobility shift of CBP1680-2441. (A) Amino acid sequence of five putative HIPK2 phosphorylation 
sites in the C-terminal part of CBP. Serine 2361, 2363, 2371, 2376, and 2381 were numbered 1 
to 5, respectively, to indicate the various individual or combined serine to alanine mutations in 
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CBP1680-2441. Western blot analysis of wild-type (wt) or mutant C-terminal fragments (CBP1680-
2441) co-expressed with HIPK2 in HEK 293T cells. Equal amounts of wt or mutant pcDNA3-
CBP1680-2441-2xFLAG constructs and either pcDNA3 (-), pCMV-SPORT6-HIPK2 (+), or the 
kinase-dead mutant pCMV-SPORT6-HIPK2-K221R (KD) were co-transfected, and 24 hr later, 
cellular extracts were prepared and analyzed on a 6% SDS-PAGE, followed by Western 
immunoblotting using anti-FLAG antibody. The 125 kDa cytoskeletal protein vinculin was used 
as a loading control. The position of CBP1680-2441 in the absence of HIPK2 (-) or in the presence 
of the kinase-dead mutant (KD) is indicated by a black arrow, whereas the slow migrating form 
is marked by an empty arrow. (B) In vitro phosphorylation of wild-type (wt) or mutant (5SA) 
GST-CBP2161-2441. GST-CBP2161-2441 (GST-CBP10) proteins were incubated with -
32
P-ATP in 
the presence (+) or in the absence (-) of human recombinant active HIPK2 (rHIPK2). The top 
panel shows the 
32
P-labeled GST-CBP10 proteins, and the lower panel the Coomassie-stained 
gel. The serine to alanine mutation of the five putative HIPK2 phosphorylation sites reduces, but 
does not completely abolish, the in vitro phosphorylation of CBP2161-2441. These results suggest 
that HIPK2 phosphorylates the C-terminal part of CBP on other sites than those involved in the 
induction of the mobility shift. 
 
 
Fig. 6. HIPK2 increases the transcriptional activity of Gal4-CBP independently of Serine 2361-
2381 phosphorylation. HEK 293T cells were transfected with 1 μg of Gal4-LUC, 2 μg of 
pcDNA3-Gal4-CBP-2xFLAG wild-type or with the five serine to alanine mutations (5SA), 
and either 1.5 μg of pcDNA3 (-), pCMV-SPORT6-HIPK2 (+), or the kinase-dead mutant 
pCMV-SPORT6-HIPK2-K221R (KD). pcDNA3 was used to normalize the amounts of DNA to 
8 μg for each condition. Cellular extracts were prepared 24 hr after transfection and analyzed for 
luciferase activity. Values were normalized for protein levels. Results are displayed as the mean 
± SEM (n=3) relative luciferase activity. * p<0.05, *** p<0.001 vs respective condition w/o 
HIPK2 (two-way ANOVA, Fisher LSD test). The effect of 5S to A mutations on HIPK2-
mediated CBP activation is not statistically significant (p=0.318). 
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Fig. 7. HIPK2 counteracts the inhibitory activity of the CRD1 domain of CBP located between 
the amino acids 977 and 1076. HEK 293T cells were transfected with 1 μg of Gal4-LUC, 2 μg of 
various pcDNA3-Gal4-CBP-2xFLAG constructs, as indicated, and either 1.5 μg of pcDNA3 (-), 
or pCMV-SPORT6-HIPK2 (+). pcDNA3 was used to normalize the amounts of DNA to 8 μg for 
each condition. Cellular extracts were prepared 24 hr after transfection and were diluted 100-fold 
for the analysis of luciferase activity, except for the HAT domain (1232-1711) and the C-
terminal fragment (1232-2441) that have a moderate transcriptional activity. Values were 
normalized for protein levels. Results are displayed as the mean ± SEM (n=3) relative luciferase 
activity. * p<0.05, *** p<0.001 vs respective condition w/o HIPK2 (two-way ANOVA, Fisher 
LSD test). 
 
 
Fig. 8. HIPK2 counteracts the repressive effect of the CRD1 domain that is devoid of HIPK2 
phosphorylation site. HEK 293T cells were transfected with 1 μg of Gal4-LUC, 2 μg of 
pcDNA3-Gal4-CBP1-682-2xFLAG or pcDNA3-Gal4-CBP1-682 + 977-1076-2xFLAG constructs, as 
indicated, and either 1.5 μg of pcDNA3 (-), pCMV-SPORT6-HIPK2 (+), or the kinase-dead 
mutant pCMV-SPORT6-HIPK2-K221R (KD). pcDNA3 was used to normalize the amounts of 
DNA to 8 μg for each condition. Cellular extracts were prepared 24 hr after transfection and 
analyzed for luciferase activity. Values were normalized for protein levels. Results are displayed 
as the mean ± SEM (n=3) relative luciferase activity. *** p<0.001 vs Gal-CBP1-682 + 977-1076 w/o 
HIPK2 condition (two-way ANOVA, Fisher LSD test). The CRD1 domain comprised between 
the amino acids 977 and 1076 of CBP does not contain any putative HIPK2 phosphorylation 
sites. 
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Abstract 
 
CREB-binding protein (CBP) and p300 are transcriptional coactivators involved in numerous 
biological processes that affect cell growth, transformation, differentiation, and development. In 
this study, we provide evidence of the involvement of homeodomain-interacting protein kinase 2 
(HIPK2) in the regulation of CBP activity. We show that HIPK2 interacts with and 
phosphorylates several regions of CBP. We demonstrate that serines 2361, 2363, 2371, 2376, 
and 2381 are responsible for the HIPK2-induced mobility shift of CBP C-terminal activation 
domain. Moreover, we show that HIPK2 strongly potentiates the transcriptional activity of CBP. 
However, our data suggest that HIPK2 activates CBP mainly by counteracting the repressive 
action of cell cycle regulatory domain 1 (CRD1), located between amino acids 977 and 1076, 
independently of CBP phosphorylation. Our findings thus highlight a complex regulation of CBP 
activity by HIPK2, which might be relevant for the control of specific sets of target genes 
involved in cellular proliferation, differentiation and apoptosis. 
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